Joint Bookrunner on Biomea Fusion, Inc.'s Follow-On Offering

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $30.00 per share. The gross proceeds to Biomea from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $172.5 million. The underwriters exercised an overallotment option in full.

Biomea is a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION ™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to target key drivers of cancer and metabolic diseases, including diabetes. Biomea is a leader in advancing next-generation covalent small molecule medicines. Biomea aims to cure.